For media inquiries: Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206-769-9219
April 23, 2026
Mozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with Stage 3 Type I Diabetes
May 7, 2025
Mozart Therapeutics Presents Preclinical Data Showing Restoration of CD8 Treg Functionality in Type 1 Diabetes and Early Data from their Targeted IL-15 Program at Immunology 2025™
March 17, 2025
Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg
More news Releases
